Sabra Health Care REIT, Inc.

As of October 31, 2025, Sabra Health Care REIT, Inc. shows a mildly bullish technical trend despite mixed signals from various indicators and underperformance compared to the S&P 500 over the past year and five years.

As of October 31, 2025, Sabra Health Care REIT, Inc. shows a mildly bullish technical trend, supported by daily moving averages, despite mixed signals from other indicators and underperforming the S&P 500 with a year-to-date return of 2.89% compared to 16.30%.

As of October 31, 2025, Sabra Health Care REIT, Inc. shows a mildly bullish trend, supported by daily moving averages and monthly Bollinger Bands, but mixed signals from MACD and KST indicate caution due to underperformance compared to the S&P 500.

As of October 3, 2025, Sabra Health Care REIT, Inc. has a mildly bullish technical trend despite recent underperformance compared to the S&P 500, with weekly indicators showing bearish signals and year-to-date returns of 3.35% versus the S&P 500's 14.18%.

As of October 3, 2025, Sabra Health Care REIT, Inc. shows a mildly bullish trend with mixed technical signals, having underperformed the S&P 500 recently, with returns of -3.66% and -4.53% over the past week and month, respectively.

As of October 3, 2025, Sabra Health Care REIT, Inc. shows a mixed technical stance with a slight bullish bias, having underperformed the S&P 500 recently but maintaining a positive year-to-date return of 4.73%.

As of September 26, 2025, Sabra Health Care REIT, Inc. shows a bullish trend with strong indicators, despite mixed signals in longer time frames, having returned 0.64% over the past week while lagging behind the S&P 500 year-to-date.

As of September 26, 2025, Sabra Health Care REIT, Inc. shows a bullish technical trend, supported by positive MACD and moving averages, despite mixed signals from other indicators and underperformance compared to the S&P 500 over the long term.

As of September 11, 2025, Sabra Health Care REIT, Inc. shows a bullish trend with mixed signals, as MACD and moving averages are bullish, but KST and Dow Theory present some caution, while the stock has underperformed the S&P 500 over the past year and five years.

As of February 27, 2024, Sabra Health Care REIT, Inc. has improved its valuation grade to very attractive, appearing undervalued with favorable P/E, PEG, and EV to EBITDA ratios compared to peers, despite a recent short-term decline in stock performance.

As of February 27, 2024, Sabra Health Care REIT, Inc. is considered undervalued with a strong growth potential, reflected in its attractive P/E ratio of 27, an EV to EBITDA of 9.20, a PEG ratio of 0.18, a high dividend yield of 653.29%, and a 1-year stock return of 26.98%, outperforming the S&P 500's 10.26%.

As of June 17, 2025, Sabra Health Care REIT, Inc. has shifted to a bullish technical trend, supported by positive daily moving averages, weekly MACD, and strong performance relative to the S&P 500, despite a mildly bearish monthly MACD.

As of March 2022, the management team of Sabra Health Care REIT, Inc. includes Chairman and CEO Richard Matros, Lead Independent Director Michael Foster, Directors Katie Cusack, Ann Kono, Clifton Porter, and Independent Director Craig Barbarosh, who oversee the company's operations and strategy.

Sabra Health Care REIT, Inc. is a real estate investment trust focused on healthcare properties, with a market cap of approximately $4.32 billion. As of March 2025, it reported net sales of $186 million and a net profit of $40 million.

As of Jun 18, Sabra Health Care REIT, Inc. has a market capitalization of $4.32 billion, with net sales of $714.38 million and a net profit of $140.77 million over the latest four quarters. The company reported shareholder's funds of $2.74 billion and total assets of $5.30 billion as of Dec 24.